FDA extends Zevalin's indication in follicular NHL
This article was originally published in Scrip
The US FDA has granted an expanded indication to Spectrum Pharmaceuticals' CD20-directed radiotherapeutic antibody Zevalin (ibritumomab tiuxetan) – for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) who achieve a partial or complete response to first-line chemotherapy.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.